Clinical Trial Update: To Assess the Glycosphingolipid Clearance and Clinical Effects of Switching to Agalsidase Beta (Fabrazyme) Versus Continuing on Agalsidase Alfa (Replagal) in Male Patients With Classic Fabry Disease [Phase 4]

View source ↗

Summary

A Phase 4 trial comparing switching from Agalsidase Alfa to Agalsidase Beta in male patients with classic Fabry disease has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fabry Disease

Drugs mentioned

• agalsidase alfa (agalsidase alfa)
• agalsidase beta (agalsidase beta)

Snippet

Sponsor: Sanofi | Conditions: Fabry Disease | Phase 4 | Status: WITHDRAWN